Pfizer

Photo
11.09.2024 • TopicsChemistry

The Evolution of the CDMO Industry

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.

Photo
09.08.2024 • News

Pfizer Invests $100 Million to Upgrade Australian Site

Pfizer is investing nearly $100 million in a major upgrade to its manufacturing facility in Melbourne, Australia, that is intended to produce new antimicrobial treatments to address rising levels of antimicrobial resistance.

Photo
23.06.2023 • News

US Senators Seek Answers on Drug Shortages

In what is being billed as a bipartisan effort to address shortages along the US pharmaceutical supply chain, two senators — one Democrat, one Republican — have introduced legislation that calls for an investigation of the problems and development of a plan to reduce the country’s dependence on imported drugs.

Photo
30.05.2023 • News

EU and Pfizer/BioNTech Amend Vaccine Pact

The European Commission and vaccine makers Pfizer and BioNTech have reached agreement on amending the bloc’s 2021 supply deal for the duo’s Comirnaty mRNA-based shot. The compromise that extends the last planned delivery date to 2026 follows months of discussion, with member states urging the Commission to renegotiate the controversial deal.

Photo
17.05.2023 • NewsStrategy

Navigating Uncertainty in the Biopharma Market

Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.

Photo
11.04.2023 • News

Court Threatens to Topple FDA’s Abortion Drug Approval

Conflicting decisions by federal courts in Texas and Washington on separate lawsuits involving mifepristone, one of the two drugs most widely used in medication-induced abortions, dominated US news over the Easter weekend. One of the rulings is thought likely to be challenged all the way to the Supreme Court.

Photo
05.04.2023 • News

Germany’s Merck Ends Bavencio Pact with Pfizer

Germany’s Merck will regain exclusive worldwide rights to develop, manufacture and commercialize the anti-programmed death ligand-1 (PD-L1) antibody Bavencio (avelumab) following the termination of its Alliance agreement with US drugs giant Pfizer, planned for the end of the second quarter.

Photo
21.03.2023 • News

Global Pharma Reduces Marketing Staff in India

As part of what seems to be a general pattern of staff reductions in the pharmaceutical industry worldwide, a growing number of Western drugmakers are downsizing their sales and marketing presence in India.

Photo
15.03.2023 • News

Pfizer Takes Seagen for $43 Billion

Pfizer has agreed to acquire Seagen, a global biotech focused on developing cancer treatments, for $43 billion. The announcement comes just a couple of weeks after the Wall Street Journal reported that the two companies were in talks.

Photo
01.03.2023 • News

Pfizer in Talks to Take Cancer Biotech Seagen

Pfizer is in the early stage of talks to acquire Seagen (formerly Seattle Genetics), a US biotech focused on developing treatments for cancer, according to a report in the Wall Street Journal that cited people familiar with the matter. The purchase price could potentially be more than $30 billion.

Photo
17.02.2023 • News

Aristea Halts Clinical Trial, Dissolves Company

Safety findings in Phase 2 clinical trials have forced Aristea Therapeutics to stop developing its lead candidate RIST4721 for treating serious immune-mediated inflammatory diseases. As a consequence, Aristea’s management has decided to dissolve the company.

Photo
17.02.2023 • News

Pfizer CEO's Texts with EC Chief Trigger Lawsuit

Two years after European Commission president Ursula von der Leyen and Pfizer CEO Albert Bourla virtually wrapped up a major order for the Covid-19 vaccine Comirnaty that the US drugmaker markets with Germany’s BioNTech, the New York Times is suing the Commission in the European Court of Justice for its failure to make essential details of the negotiations public.

Photo
10.01.2023 • News

Viatris Forms Eye Care Unit from Acquisitions

Viatris, formed in November 2020 from the merger of Mylan with Pfizer’s Upjohn division, has established an eye care division following the closure of two acquisitions on Jan. 3.

Photo
16.12.2022 • News

Chinese Distributor Inks Paxlovid Deal with Pfizer

As Covid cases continue to explode across the country, China Meheco Group Co, an internationally active manufacturer and distributor of pharmaceuticals chemicals and biologicals as well as Chinese traditional medical products, has struck a deal with Pfizer to distribute the US pharma giant’s oral antiviral Paxlovid in the People’s Republic.

Photo
15.12.2022 • News

Pfizer to Invest $750 million in Michigan

Pfizer is planning to invest $750 million in its Kalamazoo County, Michigan, production site – one of its biggest – to increase output of injectables and vaccines, including the investigational mRNA flu shot currently in Phase 3 clinical trials.

Photo
08.12.2022 • News

Pfizer Files Rebuttal of Moderna’s Patent Claim

Faced with a lawsuit from US rival Moderna, alleging that Pfizer and its German partner BioNTech infringed one of its patent for their top-selling Covid-19 vaccine Comirnaty, the New York US drugs giant said in a court filing that Comirnaty was based on independent research and wasn’t a Moderna copy.

Photo
28.10.2022 • News

Omicron-targeted Covid Boosters may not be Better

The newly launched bivalent mRNA-based Covid-19 booster shots from Moderna and Pfizer/BioNTech did not show a major improvement over the companies’ first-generation vaccines targeting the original strain, a small US study conducted by Columbia University and the University of Michigan has found. Detailed data have not yet been released.

Photo
20.10.2022 • News

EU Public Prosecutor Probes Vaccine Mega Order

The European Public Prosecutors Office (EPPO) has confirmed that it is looking into the EU Commission’s ordering of Covid-19 vaccines, with the probe thought to pertain in particular to order activity outside the usual purchasing channels.

Photo
27.09.2022 • News

Unilever Chief to Quit sooner after failed GSK Bid

British-multinational consumer products giant Unilever has announced that its chief executive, Alan Jope, will retire at the end of 2023. The potentially earlier than planned departure announcement had been anticipated.

Photo
06.09.2022 • News

EMA’s CHMP Greenlights Omicron-1 Vaccines

The human medicines committee (CHMP) of EU drug regulator European Medicines Agency (EMA) has recommended approval of the updated Covid-19 vaccines of Pfizer-BioNTech and Moderna, combining protection against the original Omicron variant as well as the wild type that emerged in China in early 2020.

Photo
02.09.2022 • News

FDA Grants EUAs to Omicron-targeted Covid Shots

As had been widely expected, the US Food and Drug Administration (FDA) on Aug. 31 granted emergency use authorizations (EUAs) to the new Covid-19 shots developed by mRNA vaccine makers Pfizer-BioNTech and Moderna.

381 more articles

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.